What guidance did Inogen's management provide for the next earnings period?

What is Inogen's latest dividend and current dividend yield?

Did Inogen beat or miss consensus estimates last quarter?

What is the market's earnings forecast for Inogen next quarter?

What is the revenue and EPS growth rate for Inogen year over year?

What were the key takeaways from Inogen's earnings call?

What is Inogen's gross profit margin?

What does Inogen do and what are its main business segments?

**Key Takeaways**
- **Revenue Momentum**: Q3 2025 revenue of $92.4 million, driven by 18.8% international B2B growth and 6.6% domestic B2B expansion.
- **Profitability Improvement**: Adjusted EBITDA of $2.3 million, up from $0.5 million, with operating expenses down 1.4%.
- **Innovation Breakthrough**: Voxi 5 launch targets 90% of oxygen therapy patients, with 2026 revenue impact. Simeox trials advancing in Europe and China.
- **Strategic Growth**: COPD market presents $600 million opportunity, with international expansion into Europe and China planned.

**【CEO Summary Section】**
- **Revenue Growth**: Reported $92.4 million in Q3 2025, marking the 7th consecutive quarter of mid-single-digit growth. Domestic B2B revenue increased 6.6% to $24.9 million, while international B2B rose 18.8% to $38.4 million.
- **Strategic Priorities**: Focused on top-line growth, profitability, and innovation. Launched Voxi 5, a stationary oxygen concentrator, to expand into the 90% of patients needing stationary units. Progress on Simeox, a bronchial decongestion solution, with limited U.S. market release and trials in Europe and China.
- **Market Expansion**: International B2B growth driven by Europe and new geographies, with China as a future target. COPD market presents a $600 million conversion opportunity.

**【CFO Financial Commentary】**
- **Financial Results**: GAAP net loss of $5.3 million (down from $6 million), adjusted EBITDA of $2.3 million (up from $0.5 million). Operating expenses decreased 1.4% to $48.4 million. Positive operating cash flow of $4.6 million (excluding one-time expenses).
- **Gross Margin**: 44.7%, down 182 basis points due to higher B2B sales mix. Rental gross margin declined 470 basis points, partly due to Medicare mix and capped patients.
- **Guidance**: Full-year revenue expected $354-357 million (6% YoY growth), adjusted EBITDA $2 million. Q4 revenue projected $87-90 million (10% YoY growth).

**【Q&A Key Highlights】**
- **International Growth**: Europe led Q3 expansion, with new markets planned. China entry in progress via UL Medical partnership.
- **Voxi 5**: Minimal Q3 impact, significant 2026 contribution. Targets 90% of oxygen therapy patients needing stationary units.
- **Simeox**: European and Chinese trials for reimbursement. U.S. limited market release building clinician awareness.
- **Rental Margin**: Pressure from Medicare mix and capped patients, but stabilization expected. One-time logistic adjustment impacted Q3 margins.

INGN

INGN fundamentals

You can ask Aime